Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.

about

Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.

Item

http://www.wikidata.org/entity/Q38912282

description

2015 nî lūn-bûn

@nan

2015年の論文

@ja

2015年学术文章

@wuu

2015年学术文章

@zh-cn

2015年学术文章

@zh-hans

2015年学术文章

@zh-my

2015年学术文章

@zh-sg

2015年學術文章

@yue

2015年學術文章

@zh

2015年學術文章

@zh-hant

name

Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.

@en

type

Item

label

Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.

@en

prefLabel

Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.

@en

P1476

Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.

@en

P2093

Barbara Savoldo

http://www.w3.org/2001/XMLSchema#string

Leslie E Huye

http://www.w3.org/2001/XMLSchema#string

Serena Kimi Perna

http://www.w3.org/2001/XMLSchema#string

P2860

Cancer regression in patients after transfer of genetically engineered lymphocytes

Combining a CD20 chimeric antigen receptor and an inducible caspase 9 suicide switch to improve the efficacy and safety of T cell adoptive immunotherapy for lymphoma

Association of PD-1, PD-1 ligands, and other features of the tumor immune microenvironment with response to anti-PD-1 therapy

B-cell depletion and remissions of malignancy along with cytokine-associated toxicity in a clinical trial of anti-CD19 chimeric-antigen-receptor-transduced T cells

Pediatric posttransplant relapsed/refractory B-precursor acute lymphoblastic leukemia shows durable remission by therapy with the T-cell engaging bispecific antibody blinatumomab.

Current concepts in the diagnosis and management of cytokine release syndrome.

Managing cytokine release syndrome associated with novel T cell-engaging therapies.

Cytotoxic T lymphocytes simultaneously targeting multiple tumor-associated antigens to treat EBV negative lymphoma.

Activity of broad-spectrum T cells as treatment for AdV, EBV, CMV, BKV, and HHV6 infections after HSCT.

P304

55-63

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/ITT.S31389

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-03-19T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

27471712

http://www.w3.org/2001/XMLSchema#string

P932

4918257

http://www.w3.org/2001/XMLSchema#string